Impact of empiric antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) infection and associated Clostridioides difficile infection (CDI) risk: Secondary analysis of the CLEAR trial

Infect Control Hosp Epidemiol. 2021 Dec;42(12):1493-1496. doi: 10.1017/ice.2020.1412. Epub 2021 Apr 16.

Abstract

We performed secondary analyses of a postdischarge decolonization trial of MRSA carriers that reduced MRSA infection and hospitalization by 30%. Hospitalized MRSA infection was associated with 7.9 days of non-MRSA antibiotics and CDI in 3.9%. Preventing MRSA infection and associated hospitalization may reduce antibiotic use and CDI incidence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aftercare
  • Anti-Bacterial Agents / therapeutic use
  • Clostridium Infections* / drug therapy
  • Clostridium Infections* / epidemiology
  • Clostridium Infections* / prevention & control
  • Cross Infection* / drug therapy
  • Cross Infection* / epidemiology
  • Cross Infection* / prevention & control
  • Humans
  • Methicillin-Resistant Staphylococcus aureus*
  • Patient Discharge
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / epidemiology
  • Staphylococcal Infections* / prevention & control

Substances

  • Anti-Bacterial Agents